Showing results (31-40 of 414) with videos related to
Sort By:
Pageof 42
Endocrinology and Metabolism Clinics of North America|July 21, 1998
Biochemical markers of bone turnover. Applications for osteoporosisP Garnero, P D DelmasBone|July 12, 2002
The impact of osteoporosis on quality-of-life: the OFELY cohortA R Martin, E Sornay-Rendu, J M Chandler, et al.Clinical Chemistry|March 29, 2001
Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosisP Garnero, O Borel, P D DelmasRheumatology (Oxford, England)|April 4, 2001
Urinary excretion of glucosyl-galactosyl pyridinoline: a specific biochemical marker of synovium degradationE Gineyts, P Garnero, P D DelmasBone|May 10, 2001
The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of boneP Garnero, S Christgau, P D DelmasBone|June 22, 1999
A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnoverP Garnero, C Darte, P D DelmasOsteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|December 13, 2005
The role of collagen in bone strengthS Viguet-Carrin, P Garnero, P D DelmasJournal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 1, 1994
Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitroP Garnero, M Grimaux, P Seguin, et al.Bone|June 1, 2000
Monitoring individual response to hormone replacement therapy with bone markersP D Delmas, P Hardy, P Garnero, et al.Bone|March 16, 2024
Postmenopausal women with normal BMD who have fractures have deteriorated bone microarchitecture: A prospective analysis from The OFELY studyE Sornay-Rendu, F Duboeuf, R D ChapurlatPageof 42